Clinical Cancer Drugs publishes original research, full-length reviews/ mini-reviews, and thematic issues in all core areas of translational and clinical cancer drug research.
The journal publishes pre-clinical and clinical studies on the development of new anti-cancer agents. Clinical studies of new reported anti-cancer drugs include Phase 1–IV clinical trial studies, their designs, research methodologies, and analyses. The journal is essential reading for clinical oncologists, toxicologists, medicinal chemists, and pharmacologists.
Bianca Maria Veneziani, Micaela Montanari, Maria Letizia Cataldo, Luigi Coppola, Agostina Nardone, Sara Corvigno, Carmine De Angelis, Grazia Arpino, Mario Giuliano, Chiara Carlomagno, Roberto Bianco and Sabino De Placido
Anna R. Schreiber, Anna Nguyen, Stacey M. Bagby, John J. Arcaroli, Betelehem W. Yacob, Kevin Quackenbush, Joe L. Guy, Thomas Crowell, Bradley Stringer, Hadi Danaee, Thea Kalebic, Wells A. Messersmith and Todd M. Pitts*